Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Sarepta Therapeutics

Status and phase: Completed; Phase 2

Conditions: Duchenne Muscular Dystrophy (DMD)

Treatments: Drug: eteplirsen

Study type: Interventional

Funder types: Industry

Identifiers

NCT02420379

4658-203

Details and patient eligibility

About

This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

Full description

Safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients.

Clinical efficacy, including functional tests and MRI, will be assessed at regularly scheduled study visits. Patients will undergo one baseline and one follow-up muscle biopsy.

Population and serial PK will be collected.

Enrollment: 33 patients

Sex: Male

Ages: 4 to 6 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male 4-6 years of age.
• Diagnosis of DMD, genotypically confirmed.
• Stable dose of oral corticosteroids for at least 12 weeks or has not received corticosteroids for at least 12 weeks.
• Intact right and left biceps muscles or two alternative upper arm muscle groups.
• Parent that is willing to provide consent and comply with study procedures.

Exclusion criteria

• Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids).
• Previous or current treatment with any other experimental treatments within 12 weeks or participation in any other clinical trial within 6 months.
• Major surgery within 3 months prior to the first dose of study drug, or planned surgery during this study which would interfere with the ability to perform study activities.
• Presence of other clinically significant illness.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

33 participants in 2 patient groups

Open-Label

Experimental group

Description:

Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .

Treatment:

Drug: eteplirsen

Control Group

No Intervention group

Description:

Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.